Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abingworth brings in new leadership

This article was originally published in Clinica

Executive Summary

Abingworth, the international investment group focused on healthcare and life sciences, has appointed Tim Haines and Kurt von Emster joint managing partners. They succeed Stephen Bunting, who takes on the role of chairman. Mr Haines, who is based in London, has been with Abingworth since 2005, while Mr von Emster, based in California, joined the firm in January this year. Mr Bunting commented that the “new and younger leadership will build on all that has been achieved to date with new insights and energy”. Abingworth has funds under management of voer $1.25bn. Its medtech investments in its latest Bioventures VI fund include corneal crosslinking specialist Avedro and medical imaging company Median Technologies. Other medtech companies in Abingworth’s portfolio have included, among others, Lombard Medical and Epigenomics, who both went public, and Pathwork Diagnostics, which was acquired by Response Genetics.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel